Methods and compositions for protection against lentiviral infections
AssigneeThe Scripps Research Institute
InventorsMatthew Gardner, Michael Farzan
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for optimally co-expressing in a primate subject a tyrosylprotein sulfotransferase (TPST) and a lentiviral gp120-binding molecule to provide potent and long term protection against lentiviral infections.
Claims14
A therapeutic composition comprising (a) a first polynucleotide sequence expressing a tyrosylprotein sulfotransferase (TPST), and (b) a second polynucleotide sequence expressing a fusion polypeptide comprising
- (i) a CCR5 mimetic comprising SEQ ID NO:
- 21 that binds a gp120 protein of a primate lentivirus,
- (ii) a CD4 polypeptide having at least 90% sequence identity to SEQ ID NO:
- 3 or SEQ ID NO:
- 4, and
- (iii) an immunoglobulin Fc domain;
- wherein the molar ratio of the first polynucleotide sequence to the second polynucleotide sequence, or the molar ratio of the TPST expressed from the first polynucleotide sequence to the fusion polypeptide expressed from the second polynucleotide sequence, is at least 1:2.
An expression system, comprising a polynucleotide sequence that expresses a first polypeptide and a second polypeptide at a molar ratio of at least 1:2, wherein the first polypeptide is a tyrosine-protein sulfotransferase (TPST) 1 or TPST2, and the second polypeptide is a fusion protein comprising
- (i) a CCR5 mimetic comprising SEQ ID NO:
- 21 that binds a gp120 protein of a primate lentivirus,
- (ii) a CD4 polypeptide having at least 90% sequence identity to SEQ ID NO:
- 3 or SEQ ID NO:
- 4, and
- (iii) an immunoglobulin Fc domain.
Dependencies are inferred from the claim text.